Journal Article

Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern

Author(s)

Adonis A Rubio/Stanford School of Medicine; Stanford University
Viren A Baharani/Rockefeller University
Bernadeta Dadonaite/Fred Hutchinson Cancer Center
Megan Parada/Stanford University
Morgan E Abernathy/Stanford University
Zijun Wang/Rockefeller University
Yu E Lee/Stanford University
Michael R Eso/Stanford University
Jennie Phung/Stanford University
Israel Ramos/Stanford University
Teresia Chen/Stanford University
Gina El Nesr/Stanford School of Medicine
Jesse D Bloom/Fred Hutchinson Cancer Center; HHMI
Paul D Dieniasz/Rockefeller University; HHMI
Michel C Nussenzweig/Rockefeller University; HHMI
Christopher O Barnes/Stanford University; Chan Zuckerberg Biohub

Publisher

Science Translational Medicine

Publication Date

March 5, 2025

DOI

10.1126/scitranslmed.adq5720

© 2026 SLAC National Accelerator Laboratory is operated by Stanford University for the U.S. Department of Energy Office of Science.